<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01260155</url>
  </required_header>
  <id_info>
    <org_study_id>E5501-A001-005</org_study_id>
    <nct_id>NCT01260155</nct_id>
  </id_info>
  <brief_title>A Single-Center, Open-Label, Randomized, 3-Treatment Crossover Bioavailability Study of Single Oral Doses of E5501 Old Tablet Formulation Under Fasted Conditions and a New Tablet Formulation Under Fed and Fasted Conditions in Healthy Subjects</brief_title>
  <official_title>A Single-Center, Open-Label, Randomized, 3-Treatment Crossover Bioavailability Study of Single Oral Doses of E5501 Old Tablet Formulation Under Fasted Conditions and a New Tablet Formulation Under Fed and Fasted Conditions in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <brief_summary>
    <textblock>
      This study will be a single-center, open-label, randomized, 3-treatment crossover
      bioavailability study of single oral doses of E5501 old tablet formulation under fasted
      conditions and a new tablet formulation administered under fed and fasted conditions in
      healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the bioavailability (BA) of E5501 in one 40 mg new tablet formulation relative to two 20 mg old tablet formulation.</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the effect of a high fat meal on the BA of E5501 in one 40 mg new tablet formulation</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety of E5501 in healthy subjects.</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Treatment A Fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B Fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C Food Effect</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E5501</intervention_name>
    <description>Treatment A: 40 mg new tablet formulation (1 tablet) under fasted conditions</description>
    <arm_group_label>Treatment A Fasted</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E5501</intervention_name>
    <description>Treatment B: 20 mg old tablet formulation (2 tablets) under fasted conditions</description>
    <arm_group_label>Treatment B Fasted</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E5501</intervention_name>
    <description>Treatment C: 40 mg new tablet formulation administered with food</description>
    <arm_group_label>Treatment C Food Effect</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Normal healthy adult males and females (age 18-45 years)

          -  Body Mass Index (BMI) greater than or equal to 18 and less than or equal to 32 at the
             time of Screening

          -  All females must have a negative serum human beta-chorionic gonadotropin test result
             or negative urine pregnancy test result at Screening and Baseline. Females of
             child-bearing potential must use a medically acceptable method of contraception
             throughout the entire study period and for 30 days after study drug discontinuation.
             Postmenopausal women and women who have been surgically sterilized or are proven
             sterile are exempt from this requirement. All women who are of reproductive potential
             and who are using hormonal contraceptives must have been on a stable dose of the same
             hormonal contraceptive product for at least 4 weeks prior to dosing and must continue
             to use the same contraceptive during the study and for 30 days after study drug
             discontinuation.

          -  Male subjects who are not abstinent or have not undergone a successful vasectomy, who
             are partners of women of child-bearing potential must use, or their partners must use,
             a highly effective,method of contraception starting for at least one menstrual cycle
             prior to starting study drug(s) and throughout the entire study period and for 30 days
             after the last dose of study drug.

          -  Willing and able to comply with all aspects of the protocol

          -  Provide written informed consent

        Exclusion Criteria:

          -  Standard selection criteria typically used in all protocols

          -  Clinically significant abnormal laboratory test results, including platelet count and
             electrolyte abnormalities at Screening and at each Baseline
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franklin Johnson</last_name>
    <role>Study Director</role>
    <affiliation>Eisai Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2010</study_first_submitted>
  <study_first_submitted_qc>December 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2010</study_first_posted>
  <last_update_submitted>October 31, 2013</last_update_submitted>
  <last_update_submitted_qc>October 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

